Product Information

Product Name Levalbuterol Hydrochloride
IUPAC Name (R) – α- [(tert-Butylamino) methyl] -4-hydroxy-m-xylene- α, α’-
diol hydrochloride
CAS No. 50293-90-8
Molecular Formula C13H21NO3. HCl
Molecular Weight 275.77
Appearance White or practically white powder
Solubility Freely soluble in water; slightly soluble in alcohol, in chloroform
and in ether
Melting Range 187 – 195°C or 169 – 171°C
Patent Status Product patent – Out of patent
Therap.Cat Levosalbutamol or levalbuterol is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is marketed under the brand name Xopenex by Sunovion Pharmaceuticals Inc. The drug is the (R)-(−)-enantiomer of its prototype drug Salbutamol (INN) or Albuterol (USAN). It is available in some countries in generic formulations from pharmaceutical companies including Cipla, Teva, and Dey, among others.
Levosalbutamol’s bronchodilator properties give it indications in treatment of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma. Like other bronchodilators, it acts by reducing inflammation in the bronchial tubes, and thus shortening or reversing an acute “attack” of shortness of breath or difficulty breathing. Unlike some slower-acting bronchodilators, it is not indicated as a preventative of chronic bronchial inflammation